Key result
Small, dense LDL affects >76% of Japanese diabetics with coronary heart disease and its size can be increased by weight reduction, antidiabetic agents, statins, and fibrates.
Why the study?
What are the clinical associations of small dense LDL and which treatments can increase LDL size?
What are the clinical associations of small dense LDL and which treatments can increase LDL size?
Small dense LDL is a marker of atherogenic dyslipidemia prevalent in various metabolic conditions, and its size can be favorably modified by lifestyle and pharmacological interventions.
No takes yet. Share an insight, caveat, or question.
Small dense LDL frequency was associated with CHD risk in Japanese diabetics; hypothesis-generating for targeted interventions.
Yoshino et al. (2002) conducted a review in Small dense LDL and coronary heart disease. Weight reduction, antidiabetic agents, statins, and fibrates was evaluated. Small, dense LDL affects >76% of Japanese diabetics with coronary heart disease and its size can be increased by weight reduction, antidiabetic agents, statins, and fibrates.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: